ROIV
Roivant Sciences Ltd. · Healthcare
CEO Matthew Gline sold $517K of Roivant Sciences Ltd.
Sold$517,227
$3.70Price
139,791Shares
−10%Stake
What ROIV did after the filing
- The stock from Wed, May 25 open, $3.85
- +14.3%
- S&P 500, same days
- −1.6%
Measured over 30 trading days, to the Jul 11 close.
Traded Fri, May 20. Filed Tue, May 24, 7:00 PM ET, after the close. Returns use the May 25 open and the Jul 11 close. Not investment advice.